Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 255.10K | 238.30K | 241.20K | 236.60K | 288.80K |
| Depreciation & Amortization | -8.60K | -8.60K | -8.60K | 4.50K | 13.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 246.50K | 229.70K | 232.60K | 261.10K | 337.30K |
| Operating Income | -246.50K | -229.70K | -232.60K | -261.10K | -337.30K |
| Income Before Tax | -266.80K | -246.20K | -260.50K | -397.90K | -517.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.27 | -0.25 | -0.26 | -0.40 | -0.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -300.00 | -200.00 | -300.00 | 400.00 | 1.50K |
| Net Income | -267.00K | -246.30K | -260.70K | -397.40K | -515.40K |
| EBIT | -246.50K | -229.70K | -232.60K | -261.10K | -337.30K |
| EBITDA | -149.00K | -186.50K | -219.50K | -246.80K | -323.20K |
| EPS Basic | -0.04 | -0.04 | -0.05 | -0.08 | -0.11 |
| Normalized Basic EPS | -0.03 | -0.02 | -0.03 | -0.03 | -0.05 |
| EPS Diluted | -0.04 | -0.04 | -0.05 | -0.08 | -0.11 |
| Normalized Diluted EPS | -0.03 | -0.02 | -0.03 | -0.03 | -0.05 |
| Average Basic Shares Outstanding | 55.40M | 80.70M | 62.70M | 62.09M | 62.09M |
| Average Diluted Shares Outstanding | 55.40M | 80.70M | 62.70M | 62.09M | 62.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |